A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcγRI-streptavidin construct and microspheres coated with biotinylated-antigen

Biomolecular Engineering

Volumn 20, Issue 1, 2003, Pages 21-33

  Walsh, Mary C ^a   Banas, Jeffrey A ^a   Mudzinski, Stanley P ^a   Preissler, Mark T ^a   Graziano, Robert F ^b   Gosselin, Edmund J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MEDAREX INC   (United States)

Author keywords

Antigen presenting cells; Fc gamma RI; Latex microspheres; Vaccines

Indexed keywords

ANTIGEN; BIOTIN; FC RECEPTOR; MICROSPHERE; RECEPTOR SUBTYPE; STREPTAVIDIN; VACCINE; HYBRID PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; RECOMBINANT DNA TECHNOLOGY; T LYMPHOCYTE ACTIVATION; CELL COMMUNICATION; CELL CULTURE; CELL STRAIN U937; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; QUALITY CONTROL; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS; BIOTINYLATION; CELL COMMUNICATION; CELLS, CULTURED; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOCYTE ACTIVATION; MICROSPHERES; QUALITY CONTROL; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; STREPTAVIDIN; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; U937 CELLS;

EID: 0037213468     PISSN: 13890344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-0344(02)00089-8     Document Type: Article

References (51)

1. Bomford R. Clin. Exp. Immunol. 39:(2):1980;435-441.
2. Gupta R.K. Adv. Drug Delivery Rev. 32:(3):1998;155-172.
3. Liu W., Yang Y., Chung N., Kwang J. Avian Dis. 45:(4):2001;797-806.
4. Ramachandra L., Song R., Harding C.V. J. Immunol. 162:(6):1999;3263-3272.
5. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Immunology. 81:(4):1994;661-667.
6. Hunter S.K., Andracki M.E., Krieg A.M. Am. J. Obstet. Gynecol. 185:(5):2001;1174-1179.
7. Nixon D.F., Hioe C., Chen P.D., et al. Vaccine. 14:(16):1996;1523-1530.
8. Wilkinson K.A., Belisle J.T., Mincek M., Wilkinson R.J., Toossi Z. J. Immunol. Meth. 235:(1-2):2000;1-9.
9. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K.L. Proc. Natl. Acad. Sci. USA. 90:(11):1993;4942-4946.
10. Puri N., Weyand E.H., Abdel-Rahman S.M., Sinko P.J. Vaccine. 18:(23):2000;2600-2612.
11. O'Hagan D.T., MacKichan M.L., Singh M. Biomol. Eng. 18:(3):2001;2069-2085.
12. Brayden D.J., Baird A.W. Microbes. Infect. 3:(10):2001;867-876.
13. Pachuk C.J., McCallus D.E., Weiner D.B., Satishchandran C. Curr. Opin. Mol. Ther. 2:(2):2000;188-198.
14. Johansen P., Men Y., Merkle H.P., Gander B. Eur. J. Pharm. Biopharm. 50:(1):2000;129-146.
15. Men Y., Audran R., Thomasin C., et al. Vaccine. 17:(9-10):1999;1047-1056.
16. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., Guyre P.M. J. Immunol. 149:(11):1992;3477-3481.
17. Keler T., Guyre P.M., Vitale L.A., et al. J. Immunol. 165:(12):2000;6738-6742.
18. Wallace P.K., Tsang K.Y., Goldstein J., et al. J. Immunol. Meth. 248:(1-2):2001;183-194.
19. Liu C., Goldstein J., Graziano R.F., et al. J. Clin. Invest. 98:(9):1996;2001-2007.
20. Heijnen I.A., van Vugt M.J., Fanger N.A., et al. J. Clin. Invest. 97:(2):1996;331-338.
21. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. Ann. Hematol. 76:(6):1998;231-248.
22. van de Winkel J.G., Anderson C.L. J. Leukoc. Biol. 49:(5):1991;511-524.
23. Guyre C.A., Barreda M.E., Swink S.L., Fanger M.W. J. Immunol. 166:(4):2001;2469-2478.
24. Barnes N., Gavin A.L., Tan P.S., Mottram P., Koentgen F., Hogarth P.M. Immunity. 16:(3):2002;379-389.
25. Gavin A.L., Barnes N., Dijstelbloem H.M., Hogarth P.M. J. Immunol. 160:(1):1998;20-23.
26. Ioan-Facsinay A., de Kimpe S.J., Hellwig S.M., et al. Immunity. 16:(3):2002;391-402.
27. Deo Y.M., Graziano R.F., Repp R., van de Winkel J.G. Immunol. Today. 18:(3):1997;127-135.
28. Mentzer S.J., Guyre P.M., Burakoff S.J., Faller D.V. Cell Immunol. 101:(2):1986;312-319.
29. Vola R., Lombardi A., Tarditi L., Bjorck L., Mariani M. J. Chromatogr. B. 668:(2):1995;209-218.
30. Halpern J.L., Habig W.H., Neale E.A., Stibitz S. Infect. Immunol. 58:(4):1990;1004-1009.
31. Cronan J.E.J. J. Biol. Chem. 265:(18):1990;10327-10333.
32. Samols D., Thornton C.G., Murtif V.L., Kumar G.K., Haase F.C., Wood H.G. J. Biol. Chem. 263:(14):1988;6461-6464.
33. Green N.M. Meth. Enzymol. 184:1990;51-67.
34. Green N.M. Adv. Protein Chem. 29:1975;85-133.
35. Alpar H.O., Eyles J.E., Williamson E.D., Somavarapu S. Adv. Drug Delivery Rev. 51:(1-3):2001;173-201.
36. Singh M., Ott G., Kazzaz J., et al. Pharm. Res. 18:(10):2001;1476-1479.
37. Johansen P., Estevez F., Zurbriggen R., et al. Vaccine. 19:(9-10):2000;1047-1054.
38. Pillai O., Panchagnula R. Curr. Opin. Chem. Biol. 5:(4):2001;447-451.
39. Stoll G.H., Nimmerfall F., Acemoglu M., et al. J. Control Release. 76:(3):2001;209-225.
40. Lin C.T., Shen Z., Boros P., Unkeless J.C. J. Clin. Immunol. 14:(1):1994;1-13.
41. Duchemin A.M., Ernst L.K., Anderson C.L. J. Biol. Chem. 269:(16):1994;12111-12117.
42. Jelley-Gibbs D.M., Plitnick L.M., Gosselin E.J. Hum. Immunol. 60:(6):1999;469-478.
43. Schultz J., Lin Y., Sanderson J., et al. Cancer Res. 60:(23):2000;6663-6669.
44. Penichet M.L., Kang Y.S., Pardridge W.M., Morrison S.L., Shin S.U. J. Immunol. 163:(8):1999;4421-4426.
45. Goshorn S., Sanderson J., Axworthy D., Lin Y., Hylarides M., Schultz J. Cancer Biother. Radiopharm. 16:(2):2001;109-123.
46. Lehtolainen P., Taskinen A., Laukkanen J., et al. J. Biol. Chem. 277:(10):2002;8545-8550.
47. Weiden P.L., Breitz H.B., Press O., et al. Cancer Biother. Radiopharm. 15:(1):2000;15-29.
48. Knox S.J., Goris M.L., Tempero M., et al. Clin. Cancer Res. 6:(2):2000;406-414.
49. Paganelli G., Bartolomei M., Ferrari M., et al. Cancer Biother. Radiopharm. 16:(3):2001;227-235.
50. Grana C., Chinol M., Robertson C., et al. Br. J. Cancer. 86:(2):2002;207-212.
51. Graziano R.F., Goldstein J., Sundarapandiyan K., Somasundaram C., Keler T., Deo Y.M. Cancer Immunol. Immunother. 45:(3-4):1997;124-127.